Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

2.

Sequential systemic administrations of combretastatin A4 Phosphate and radioiodinated hypericin exert synergistic targeted theranostic effects with prolonged survival on SCID mice carrying bifocal tumor xenografts.

Li J, Cona MM, Chen F, Feng Y, Zhou L, Zhang G, Nuyts J, de Witte P, Zhang J, Yu J, Oyen R, Verbruggen A, Ni Y.

Theranostics. 2013;3(2):127-37. doi: 10.7150/thno.5790.

3.

A dual-targeting anticancer approach: soil and seed principle.

Li J, Sun Z, Zhang J, Shao H, Cona MM, Wang H, Marysael T, Chen F, Prinsen K, Zhou L, Huang D, Nuyts J, Yu J, Meng B, Bormans G, Fang Z, de Witte P, Li Y, Verbruggen A, Wang X, Mortelmans L, Xu K, Marchal G, Ni Y.

Radiology. 2011 Sep;260(3):799-807. doi: 10.1148/radiol.11102120.

PMID:
21712473
4.

An overview of translational (radio)pharmaceutical research related to certain oncological and non-oncological applications.

Cona MM, de Witte P, Verbruggen A, Ni Y.

World J Methodol. 2013 Dec 26;3(4):45-64. doi: 10.5662/wjm.v3.i4.45. Review.

5.

Necrosis targeted combinational theragnostic approach using radioiodinated Sennidin A in rodent tumor models.

Ji Y, Jiang C, Zhang X, Liu W, Gao M, Li Y, Wang J, Wang Q, Sun Z, Jiang X, Yao N, Wang X, Fang Z, Yin Z, Ni Y, Zhang J.

Oncotarget. 2014 May 30;5(10):2934-46.

6.

Combretastatin A4-phosphate and its potential in veterinary oncology: a review.

Abma E, Daminet S, Smets P, Ni Y, de Rooster H.

Vet Comp Oncol. 2017 Mar;15(1):184-193. doi: 10.1111/vco.12150.

PMID:
25988493
7.

A review on various targeted anticancer therapies.

Li J, Chen F, Cona MM, Feng Y, Himmelreich U, Oyen R, Verbruggen A, Ni Y.

Target Oncol. 2012 Mar;7(1):69-85. doi: 10.1007/s11523-012-0212-2. Review.

PMID:
22350489
8.

A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P).

Siemann DW, Chaplin DJ, Walicke PA.

Expert Opin Investig Drugs. 2009 Feb;18(2):189-97. doi: 10.1517/13543780802691068 . Review.

9.

The development of combretastatin A4 phosphate as a vascular targeting agent.

Chaplin DJ, Hill SA.

Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1491-6.

PMID:
12459376
10.

Tumor necrosis targeted radiotherapy of non-small cell lung cancer using radioiodinated protohypericin in a mouse model.

Liu X, Jiang C, Zhang D, Gao M, Peng F, Huang D, Sun Z, Ni Y, Zhang J, Yin Z.

Oncotarget. 2015 Sep 22;6(28):26400-10. doi: 10.18632/oncotarget.4568.

11.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
12.

Exploring theranostic potentials of radioiodinated hypericin in rodent necrosis models.

Li J, Cona MM, Chen F, Feng Y, Zhou L, Yu J, Nuyts J, de Witte P, Zhang J, Himmelreich U, Verbruggen A, Ni Y.

Theranostics. 2012;2(10):1010-9. doi: 10.7150/thno.4924.

13.

Preclinical efficacy of vascular disrupting agents in non-small-cell lung cancer.

Baguley BC.

Clin Lung Cancer. 2011 Mar;12(2):81-6. doi: 10.1016/j.cllc.2011.03.001. Review.

PMID:
21550553
14.

Combretastatin A4 phosphate: a novel vascular disrupting agent.

Nagaiah G, Remick SC.

Future Oncol. 2010 Aug;6(8):1219-28. doi: 10.2217/fon.10.90. Review.

PMID:
20799867
15.

Combretastatin A4 phosphate.

West CM, Price P.

Anticancer Drugs. 2004 Mar;15(3):179-87. Review.

PMID:
15014350
16.

The first international conference on vascular targeting: meeting overview.

Thorpe PE, Chaplin DJ, Blakey DC.

Cancer Res. 2003 Mar 1;63(5):1144-7.

17.

Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling.

Vincent L, Kermani P, Young LM, Cheng J, Zhang F, Shido K, Lam G, Bompais-Vincent H, Zhu Z, Hicklin DJ, Bohlen P, Chaplin DJ, May C, Rafii S.

J Clin Invest. 2005 Nov;115(11):2992-3006.

18.

Current development status of small-molecule vascular disrupting agents.

Chaplin DJ, Horsman MR, Siemann DW.

Curr Opin Investig Drugs. 2006 Jun;7(6):522-8. Review.

PMID:
16784022
19.

Synthesis and Evaluation of 131I-Skyrin as a Necrosis Avid Agent for Potential Targeted Radionuclide Therapy of Solid Tumors.

Wang C, Jin Q, Yang S, Zhang D, Wang Q, Li J, Song S, Sun Z, Ni Y, Zhang J, Yin Z.

Mol Pharm. 2015 Dec 17. [Epub ahead of print]

PMID:
26647005
20.

Small molecule vascular disrupting agents: potential new drugs for cancer treatment.

Cai SX.

Recent Pat Anticancer Drug Discov. 2007 Jan;2(1):79-101. Review.

PMID:
18221055

Supplemental Content

Support Center